194 related articles for article (PubMed ID: 23977339)
1. In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge.
Davis D; Koornstra W; Fagrouch Z; Verschoor EJ; Heeney JL; Bogers WM
PLoS One; 2013; 8(8):e72702. PubMed ID: 23977339
[TBL] [Abstract][Full Text] [Related]
2. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
[TBL] [Abstract][Full Text] [Related]
3. Induction of neutralizing antibodies against tier 2 human immunodeficiency virus 1 in rhesus macaques infected with tier 1B simian/human immunodeficiency virus.
Himeno A; Ishida Y; Mori H; Matsuura K; Kikukawa M; Sakawaki H; Miura T
Arch Virol; 2019 May; 164(5):1297-1308. PubMed ID: 30820667
[TBL] [Abstract][Full Text] [Related]
4. Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges.
Hessell AJ; Shapiro MB; Powell R; Malherbe DC; McBurney SP; Pandey S; Cheever T; Sutton WF; Kahl C; Park B; Zolla-Pazner S; Haigwood NL
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514914
[TBL] [Abstract][Full Text] [Related]
5. Cooperation Between Systemic IgG1 and Mucosal Dimeric IgA2 Monoclonal Anti-HIV Env Antibodies: Passive Immunization Protects Indian Rhesus Macaques Against Mucosal SHIV Challenges.
Gong S; Lakhashe SK; Hariraju D; Scinto H; Lanzavecchia A; Cameroni E; Corti D; Ratcliffe SJ; Rogers KA; Xiao P; Fontenot J; Villinger F; Ruprecht RM
Front Immunol; 2021; 12():705592. PubMed ID: 34413855
[TBL] [Abstract][Full Text] [Related]
6. Protection in macaques immunized with HIV-1 candidate vaccines can be predicted using the kinetics of their neutralizing antibodies.
Davis D; Koornstra W; Mortier D; Fagrouch Z; Verschoor EJ; Heeney JL; Bogers WM
PLoS One; 2011; 6(12):e28974. PubMed ID: 22216149
[TBL] [Abstract][Full Text] [Related]
7. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.
Parren PW; Marx PA; Hessell AJ; Luckay A; Harouse J; Cheng-Mayer C; Moore JP; Burton DR
J Virol; 2001 Sep; 75(17):8340-7. PubMed ID: 11483779
[TBL] [Abstract][Full Text] [Related]
8. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques.
Moldt B; Shibata-Koyama M; Rakasz EG; Schultz N; Kanda Y; Dunlop DC; Finstad SL; Jin C; Landucci G; Alpert MD; Dugast AS; Parren PW; Nimmerjahn F; Evans DT; Alter G; Forthal DN; Schmitz JE; Iida S; Poignard P; Watkins DI; Hessell AJ; Burton DR
J Virol; 2012 Jun; 86(11):6189-96. PubMed ID: 22457527
[TBL] [Abstract][Full Text] [Related]
9. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers.
Hessell AJ; Rakasz EG; Poignard P; Hangartner L; Landucci G; Forthal DN; Koff WC; Watkins DI; Burton DR
PLoS Pathog; 2009 May; 5(5):e1000433. PubMed ID: 19436712
[TBL] [Abstract][Full Text] [Related]
10. Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.
Sundling C; O'Dell S; Douagi I; Forsell MN; Mörner A; Loré K; Mascola JR; Wyatt RT; Karlsson Hedestam GB
J Virol; 2010 Sep; 84(18):9086-95. PubMed ID: 20610729
[TBL] [Abstract][Full Text] [Related]
11. Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge.
Sholukh AM; Watkins JD; Vyas HK; Gupta S; Lakhashe SK; Thorat S; Zhou M; Hemashettar G; Bachler BC; Forthal DN; Villinger F; Sattentau QJ; Weiss RA; Agatic G; Corti D; Lanzavecchia A; Heeney JL; Ruprecht RM
Vaccine; 2015 Apr; 33(17):2086-95. PubMed ID: 25769884
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
[TBL] [Abstract][Full Text] [Related]
13. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.
Baba TW; Liska V; Hofmann-Lehmann R; Vlasak J; Xu W; Ayehunie S; Cavacini LA; Posner MR; Katinger H; Stiegler G; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Lu Y; Wright JE; Chou TC; Ruprecht RM
Nat Med; 2000 Feb; 6(2):200-6. PubMed ID: 10655110
[TBL] [Abstract][Full Text] [Related]
14. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.
Gardner MR; Kattenhorn LM; Kondur HR; von Schaewen M; Dorfman T; Chiang JJ; Haworth KG; Decker JM; Alpert MD; Bailey CC; Neale ES; Fellinger CH; Joshi VR; Fuchs SP; Martinez-Navio JM; Quinlan BD; Yao AY; Mouquet H; Gorman J; Zhang B; Poignard P; Nussenzweig MC; Burton DR; Kwong PD; Piatak M; Lifson JD; Gao G; Desrosiers RC; Evans DT; Hahn BH; Ploss A; Cannon PM; Seaman MS; Farzan M
Nature; 2015 Mar; 519(7541):87-91. PubMed ID: 25707797
[TBL] [Abstract][Full Text] [Related]
15. Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.
Astronomo RD; Santra S; Ballweber-Fleming L; Westerberg KG; Mach L; Hensley-McBain T; Sutherland L; Mildenberg B; Morton G; Yates NL; Mize GJ; Pollara J; Hladik F; Ochsenbauer C; Denny TN; Warrier R; Rerks-Ngarm S; Pitisuttithum P; Nitayapan S; Kaewkungwal J; Ferrari G; Shaw GM; Xia SM; Liao HX; Montefiori DC; Tomaras GD; Haynes BF; McElrath JM
EBioMedicine; 2016 Dec; 14():97-111. PubMed ID: 27919754
[TBL] [Abstract][Full Text] [Related]
16. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques.
Santra S; Tomaras GD; Warrier R; Nicely NI; Liao HX; Pollara J; Liu P; Alam SM; Zhang R; Cocklin SL; Shen X; Duffy R; Xia SM; Schutte RJ; Pemble Iv CW; Dennison SM; Li H; Chao A; Vidnovic K; Evans A; Klein K; Kumar A; Robinson J; Landucci G; Forthal DN; Montefiori DC; Kaewkungwal J; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Robb ML; Michael NL; Kim JH; Soderberg KA; Giorgi EE; Blair L; Korber BT; Moog C; Shattock RJ; Letvin NL; Schmitz JE; Moody MA; Gao F; Ferrari G; Shaw GM; Haynes BF
PLoS Pathog; 2015 Aug; 11(8):e1005042. PubMed ID: 26237403
[TBL] [Abstract][Full Text] [Related]
17. A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection.
Gautam R; Nishimura Y; Gaughan N; Gazumyan A; Schoofs T; Buckler-White A; Seaman MS; Swihart BJ; Follmann DA; Nussenzweig MC; Martin MA
Nat Med; 2018 May; 24(5):610-616. PubMed ID: 29662199
[TBL] [Abstract][Full Text] [Related]
18. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission.
Watkins JD; Sholukh AM; Mukhtar MM; Siddappa NB; Lakhashe SK; Kim M; Reinherz EL; Gupta S; Forthal DN; Sattentau QJ; Villinger F; Corti D; Ruprecht RM;
AIDS; 2013 Jun; 27(9):F13-20. PubMed ID: 23775002
[TBL] [Abstract][Full Text] [Related]
19. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
Mascola JR; Stiegler G; VanCott TC; Katinger H; Carpenter CB; Hanson CE; Beary H; Hayes D; Frankel SS; Birx DL; Lewis MG
Nat Med; 2000 Feb; 6(2):207-10. PubMed ID: 10655111
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock.
Lopker M; Easlick J; Sterrett S; Decker JM; Barbian H; Learn G; Keele BF; Robinson JE; Li H; Hahn BH; Shaw GM; Bar KJ
J Virol; 2013 May; 87(10):5477-92. PubMed ID: 23468494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
